In recent years, the conversation around access to healthcare has focused on two important questions: how innovative is a solution, and how quickly can it reach the market? Today, there is a third question that is just as important: how prepared is the region to sustain its availability over time?
In public health, access depends on having an approved vaccine or biologic, but above all it also depends on having industrial capacity, resilient supply chains, and production close enough to the market to respond when demand changes, logistics come under pressure, or the global environment becomes less favorable.
Supply chains are playing an increasingly central role in how pharma and medtech bring therapies to market, because they affect launch speed, patient access, and overall business performance.
Leading life sciences companies in 2025 are combining innovation, efficiency, sustainability, and technology to respond to a much more complex global supply chain.
At Sinergium Biotech, this conversation is understood from a regional perspective: biopharmaceutical production is an industrial capability, but also a way to strengthen continuity, access, and health autonomy across Latin America.
Access is not enough if it cannot be sustained
A vaccine may already be incorporated into a public health strategy, recommended by international organizations, or available in certain markets. But when the region lacks the capacity to manufacture, package, or supply it consistently, that access may continue to depend on external conditions such as logistics lead times, global availability, prioritization of other markets, or trade restrictions.
This is where regional production gains value, not as a substitute for innovation, but as the component that makes access more stable, predictable, and closely aligned with the real needs of healthcare systems.
Building more resilient vaccine manufacturing ecosystems requires countries and regions to gain access to more segments of the value chain and strategically strengthen local capabilities.
Regional production: more than capacity, a way to ensure continuity
In practice, regional production means having sufficient infrastructure, technical expertise, quality systems, and coordination so that a critical product does not depend exclusively on decisions made far from where it is needed.
This strengthens continuity in several ways:
It reduces external dependence in the face of logistical or geopolitical changes, improves the ability to respond to increases in demand, shortens operational timelines by bringing production closer to its destination, and strengthens health resilience by expanding the region’s industrial base.
A tangible example
In January 2025, the Pan American Health Organization (PAHO), the Government of Argentina, Pfizer, and Sinergium Biotech announced a joint effort to advance the local production of the 20-valent pneumococcal conjugate vaccine (PCV20) in Argentina. PCV20 has been available for Latin America and the Caribbean since early 2025, while local production in Argentina is currently under development.
That is why regional production is also a conversation about health continuity and about how to sustain access to critical solutions over time when the external environment becomes more unstable.
What comes next
The public health conversation in Latin America can no longer separate access from industrial capacity. In an environment where global supply chains are increasingly sensitive, continuity depends more and more on how much the region can do for itself, and on the level of quality, coordination, and predictability with which it can do so. This is where regional production stops being a secondary element and becomes part of the solution.
At Sinergium Biotech, this approach is understood as a way to integrate manufacturing capacity, quality, and regional vision to strengthen healthcare access from a more solid industrial base. Because when the region expands its ability to produce, it also increases its ability to sustain access with greater autonomy, continuity, and resilience.
